Aytu BioPharma (NASDAQ:AYTU) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.51) by 3.92 percent. This is a 352.38 percent decrease over earnings of $0.21 per share from the same period last year. The company reported quarterly sales of $12.411 million which beat the analyst consensus estimate of $12.053 million by 2.97 percent. This is a 32.74 percent decrease over sales of $18.452 million the same period last year.